TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04361695
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03436576
Drug: Autologous Serum 50%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instillation of 1 drop of Autologous Serum 50% four times a day
Study: NCT05178745
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical Form: solution for injection Route of Administration: intravenous (IV), intravenous or intra-arterial infusion
Study: NCT00471055
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02554721
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00247052
Drug: diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: diclofenac 50 mg bid versus placebo bid
Study: NCT00247052
Drug: diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: diclofenac 100 mg per day for 14 days
Study: NCT01349491
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be started on a matching placebo twice daily. The first dose will be administered the day of cardioversion and continued for a total of six months.
Study: NCT00002649
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00609102
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one capsule BID
Study: NCT00609102
Drug: n-aceylcysteine
Normalized name: N-6022
DrugBank: N-6022 (DB12206)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 mgm BID
Study: NCT00886002
Drug: Fentanyl; Buprenorphine; Naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03570827
Drug: Androgen Suppression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given androgen suppression therapy
Study: NCT04267926
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject will receive Placebo
Study: NCT01075022
Drug: Colecalciferol (Vitamin D3) 300.000 UI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colecalciferol (Vitamin D3) 300.000 UI Capsule, Single Dose
Study: NCT01075022
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Capsule, Single Dose
Study: NCT03718065
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator.
Study: NCT01843374
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is to be administered as an IV solution, followed by observation.
Study: NCT01091116
Drug: MEN16132 - 0.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of two high doses of MEN16132 at 2-week interval
Study: NCT01091116
Drug: MEN16132 - 0.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intra-articular injection of one high dose of MEN16132, followed by one dose of placebo at 2-week interval
Study: NCT01091116
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of 2 doses of Placebo control at 2-week interval
Study: NCT00145379
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04050553
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT00865176
Drug: Eplerenone 50 mg Tablets Sandoz Inc., USA
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04450394
Drug: LY3209590
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT04236427
Drug: Angong Niuhuang Wan Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angong Niuhuang Wan Placebo 3g
Study: NCT04361708
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Leucovorin will be administered on day 1 of each cycle at 400mg/kg. The drugs will be given through the patient's Mediport. It will be given once every 14 days (2 weeks), on days 1 and will be continued for 8 doses (4 months)
Study: NCT04252872
Drug: HCP0605
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04252872
Drug: HGP1405
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04252872
Drug: HCP1401
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03029494
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: sugar pill manufactured to mimic 1000 mg Vitamin C
Study: NCT00817037
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet once daily oral dosing for 6 weeks
Study: NCT03935893
Drug: Fludarabine + Cyclophosphamide combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparative lymphocyte depleting (immunosuppressive) combination regimen consisting of fludarabine and cyclophosphamide administered prior to TIL infusion.
Study: NCT04335669
Drug: epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytotoxic agents.
Study: NCT04335669
Drug: epirubicin, cyclophosphamide, capecitabine, paclitaxel, carboplatin, pembrolizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytotoxic agents.
Study: NCT03579004
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil is used in two cycles of neoadjuvant chemotherapy
Study: NCT04053036
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be given a placebo capsule that will only contain lactose.
Study: NCT02574728
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib 100 mg will be given by mouth twice a day for six weeks (every six weeks is called one cycle) for up to two years or 16 cycles.
Study: NCT02574728
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 2.5 mg/Kg (maximum dose 100 mg) will be given daily by mouth for the second 3 weeks of a 6 week cycle. Six week cycles will be repeated for up to two years or 16 cycles.
Study: NCT02605837
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose of 10 ml of placebo matched with the experimental drug.
Study: NCT00212615
Drug: Capecitabine (Xeloda)
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01024517
Drug: GLPG0259 solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose, GLPG0259, 50 mg oral solution
Study: NCT01024517
Drug: GLPG0259
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose, GLPG0259, 50 mg solid formulation
Study: NCT00379015
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03306914
Drug: Hydroxyethylstarch 6%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of Hydroxyethylstarch 6% intra-operatively
Study: NCT02275052
Drug: UMEC/VI DPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: The DPI will contain a total of 30 doses. Each DPI will be comprised of two double-foil, laminate blister strips. Each blister of one strip will consist of 62.5mcg of UMEC blended with lactose and magnesium stearate while each blister of other strip will consist of 25 mcg of VI blended with lactose and magnesium stearate. Each actuation of the DPI will deliver the contents of one blister from each strip simultaneously
Study: NCT02275052
Drug: Placebo DPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo DPI, identical in appearance to the inhaler containing active study medication, will have two blister strips, each containing 30 blisters of lactose and magnesium stearate.
Study: NCT00705627
Drug: neoadjuvant chemotherapy plus concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: cisplatin,fluorouracil. Patients received cisplatin 80mg/m2 on day 1,fluorouracil 4000mg/m2 civ 120 hours every three weeks for two cycles, then received radical radiotherapy, and cisplatin (80mg/m2 on day 1) every three weeks for three cycles during RT.
Study: NCT04590274
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin
Study: NCT00917553
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cellulose Placebo Capsule
Study: NCT00907595
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: After 2 weeks of baseline sleep study, subjects will be randomized to take either Ramelteon or Placebo for 4 weeks.
Study: NCT04561960
Drug: Toothpaste Product
Normalized name: Toothpaste Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non Fluoridated toothpaste with extract of miswak ( Dabur, miswak tooth paste)
Study: NCT00644423
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo
Study: NCT00878501
Drug: AZD1386
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, during 4 weeks
Study: NCT00878501
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, during 4 weeks
Study: NCT04227808
Drug: Lenvima 4 mg Oral Capsule
Normalized name: Lenvima 4 MG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants will receive treatment with lenvatinib for 12 months after recruitment or until disease recurrence, intolerance AEs, or death. In case of treatment-related adverse effects, interruption or reduction is allowed.
Study: NCT02652260
Drug: ATRIPLA^TM
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single tablet FDC containing efavirenz (EFV) 600 mg, emtricitabine (FTC) 200 mg, and TDF 300 mg administered orally, once daily for 12 weeks during the Blinded period
Study: NCT00524485
Drug: aminolevulinic acid
Normalized name: Aminolevulinic Acid
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00114400
Drug: folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02247726
Drug: Saline Placebo (0.5mL injection)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01537666
Drug: AeroVanc
Normalized name: AEROVENT PLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin hydrochloride dry powder for inhalation
Study: NCT01903356
Drug: Trajenta duo
Normalized name: Effaclar Duo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linagliptin and Metformin
Study: NCT01527149
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01527149
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01527149
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03036891
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be given Placebo (Placebo 25 mg).They will take this daily in the morning 1 hour before breakfast for four weeks.
Study: NCT02723955
Drug: GSK3174998
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02610296
Drug: QPI-1002
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV injection
Study: NCT02723955
Drug: Fluorouracil (5-FU) plus carboplatin or cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00521950
Drug: azathioprine (AZA) or 6-mercaptopurine (6-MP)
Normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be advised a standard initial treatment dose:~* AZA 2-2.5 mg/kg/day or 6-MP 1-1.5 mg/kg/day (standard care);
Study: NCT02249377
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid
Study: NCT00372944
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral tablet
Study: NCT04293081
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: participants in group (B) will receive 10 ml isotonic saline (placebo) by the same route as control.
Study: NCT01326481
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral
Study: NCT01460212
Drug: SSRI antidepressants
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRI antidepressants are Selective serotonin reuptake inhibitors. They include fluoxetine (Prozac); sertraline (Zoloft); paroxetine (Paxil); citalopram (Celexa) ;escitalopram (Lexapro) and fluvoxamine (Luvox). It will be chosen according to special condition of every patient.
Study: NCT02935010
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: antibiotic for H. pylori eradication
Study: NCT03955211
Drug: HTX-011
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg
Study: NCT03955211
Drug: HTX-011
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg
Study: NCT03955211
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg
Study: NCT03955211
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 975 mg to 1 g
Study: NCT01985152
Drug: Azilsartan Trimethylethanolamine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01985152
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01524094
Drug: Systemic chemotherapy alone (oxaliplatin, 5-fluorouracil, isovorin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin 100 mg/ m2 as a 2 h iv infusion + 5-fluorouracil 400 mg/ m2 iv bolus + Isovorin 100 mg/ m2 as a 2 h infusion followed by 5-fluorouracil 2400 mg/ m2 as a 46 h infusion. Each cycle is given every other week until 12 cycles have been administered.
Study: NCT02256150
Drug: Cyclophosphamide (CTX)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01397097
Drug: LNG-IUS (BAY 86-5028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCS12 insertion will occur at randomization visit (Visit 2). Duration of study treatment is 12 months with an follow-up extension for up to 3 years
Study: NCT02950051
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide i.v.: cycles 1-6: 250 mg/m², d1-3, q28d
Study: NCT02359942
Drug: Citric acid
Normalized name: Citric Acid
DrugBank: Citric acid (DB04272)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Giving the citric acid (4g) solving in 200 ml of water before UBT
Study: NCT03687957
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: -Given by intramuscular injection
Study: NCT03974854
Drug: XELOXIRI-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: chemotherapy with XELOXIRI-3 regimen
Study: NCT02690506
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01200758
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Eight cycles of cyclophosphamide (750 mg/m\^2 IV) administered every 3 weeks.
Study: NCT01200758
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eight cycles of doxorubicin (50 mg/m\^2 IV) administered every 3 weeks.
Study: NCT04460651
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in this arm will receive placebo with the following dosage schedule: 8 g of placebo (4 capsules every 12 hours - morning and evening, with food) for the first three days followed by 4 g of placebo (2 capsules every 12 hours - morning and evening, with food) thereafter (days 4-28 for treatment arm and 4-60 for prevention arm)
Study: NCT04205240
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03033290
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo control
Study: NCT02798159
Drug: TD0025
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03359538
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets containing Rapamycin/placebo will be administered based on body surface area and adjusted taking into consideration plasma rapamycin dosage
Study: NCT00004688
Drug: mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00037843
Drug: I-131 Iodocholesterol
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03480360
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 14.5 mg/kg for 2 days (days -6, -5) and then 50 mg/kg for two days (days 3, 4)
Study: NCT00325897
Drug: Macrolide Antibiotic (Azithromycin)
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin (daily capsule, 250 mg for 12 months)
Study: NCT00325897
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo taken on a daily basis
Study: NCT04163562
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A: Oral placebo administration onces daily for 2 weeks. Part B: Oral placebo administration onces daily for 6 months.
Study: NCT02365961
Drug: ropivicaine
Normalized name: Ropivicaine-Sufentanil Citrate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02365961
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02365961
Drug: Noropin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01756482
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03054519
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pills will appear identical to the metformin to maintain blinding of participants and investigators.
Study: NCT00066716
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg orally BID begins 3-7 days before the first dose of chemotherapy to the morning of surgery. Celecoxib 400 mg orally BID will resume post-operatively 4-8 weeks if there is adequate wound healing and will be continued for 1 year total, that is, 1 year from the date of surgery + 2 weeks unless tumor recurrence is documented.
Study: NCT04619680
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo 150 mg equivalent twice a day, taken with food food (or, for Child-Pugh A patients, 100 mg by mouth twice daily).
Study: NCT02325934
Drug: Stribild, crushed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crushed Stribild tablet
Study: NCT02518594
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo softgel capsule, daily from randomization to \< 35 wks
Study: NCT03797651
Drug: Standard DAPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient will continue standard treatment (aspirin plus ticagrelor) for 1 year. Dosage of ticagrelor would be 90 mg twice a day, and 100 mg of aspirin will be prescribed once a day.
Study: NCT03797651
Drug: Very-short DAPT less than 1 month after PCI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient will stop aspirin (ticagrelor monotherapy) after discharge or within 1 month. Dosage of ticagrelor would be 90 mg twice a day, and 100 mg of aspirin will be prescribed once a day (during hospitalization).
Study: NCT01003301
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injections subcutaneously (up to 3) every 2 or 4 wks based on the subjects weight and baseline total serum IgE level as approved for therapy in allergic asthma. Duration of therapy is approximately 14 wks.
Study: NCT04435925
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loading dose: 0.5 mcg/kg Maintenance dose: 1 mcg/kg/minute
Study: NCT04435925
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Loading dose: 2 mcg/kg Maintenance dose: 0.4 mcg/kg/30-minutes
Study: NCT02663492
Drug: Sanguisorba officinalis L.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sanguisorba officinalis L., a Leukogenic medication, named Diyu Shengbai Pian (Chengdu Diao Tianfu Pharmaceutical Group Co., Ltd., China) will be taken 0.4g each time by 3 times per day.
Study: NCT00567580
Drug: AA
Normalized name: UAA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiandrogen (AA) therapy can be either 250 mg flutamide by mouth three times a day or 50 mg bicalutamide by mouth once a day.
Study: NCT00567580
Drug: LHRH agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luteinizing hormone-releasing hormone (LHRH) agonist can be any analog approved by the FDA (or by Health Canada for Canadian institutions) and may be given in any possible combination such that the total LHRH treatment time is 4-6 months. LHRH analogs are administered with a variety of techniques, including subcutaneous insertion of a solid plug in the abdominal wall, intramuscular injection, and subcutaneous injection.
Study: NCT04662385
Drug: Colgate Total
Normalized name: Colgate Total
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whitening toothpaste that removes and prevents new stains Fights bacteria on teeth, tongue, cheeks and gums for whole mouth healthy Mint toothpaste for long lasting fresh breath Helps prevent plaque, tartar, cavities \& gingivitis
Study: NCT02516696
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500mg PO twice daily on days 1-28 for a 28-day cycle.
Study: NCT04094597
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebp is given in 2 ml saline
Study: NCT04877626
Drug: Artemeter plus lumefantrina vs artesunato plus amodiquina
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 received the combination AQ+AS (COARSUCAM®) which was administered orally at an initial dose of 2 tablets (200 mg AQ/540 mg AS) followed by 2 additional doses of 2 tablets at 24 and 48 hours (6 tablets in 48 hours).~Group 2 received the combination Artemeter+lumefantrina (COARTEM®) administered orally at an initial dose of 4 tablets (80 mg artemeter/480 mg lumefantrina) followed by 5 additional doses of 4 tablets at 8, 24, 36, 48, and 60 hours (24 tablets in 60 hours)